Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have signed the consent form to participate in the REALYSA study.
- People who are 18 years of age or older at the time of joining.
- People who have been diagnosed with lymphoma within the last 6 months (180 days).
- People whose lymphoma is one of these seven specific types: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, or Burkitt lymphoma.
Who may not be able to join:
- People who have already received treatment for their lymphoma, other than a short introductory treatment using certain medicines such as steroids, vincristine, cyclophosphamide, or etoposide, given alone or together.
- People who have a documented HIV infection.
- People whose lymphoma type is not on the approved list for this trial, including the following specific types: chronic lymphocytic leukemia or small lymphocytic lymphoma, hairy cell leukemia or its variant, lymphoplasmacytic lymphoma, Waldenström macroglobulinemia, diffuse large B-cell lymphoma affecting the brain or spinal cord, T-cell large granular lymphocytic leukemia, a chronic disorder of NK immune cells, mycosis fungoides, Sézary syndrome, primary cutaneous (skin-based) T-cell lymphomas that are mainly managed by skin specialists, and lymphoma that developed after an organ or stem cell transplant.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hervé Ghesquières, MD, Hospices Civils de Lyon
Phone: 04 78 86 43 40
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-Free Survival (PFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.